FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasiiiigton,	D.C.	20049

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Treco Douglas A</u>					2. Issuer Name and Ticker or Trading Symbol Inozyme Pharma, Inc. [INZY]					(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) C/O INO	,	rst) ARMA, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/13/2024							Officer (below)	Officer (give title below) CEO Other (specify below)			
321 SUMMER STREET SUITE 400					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOSTON	N M	A	02210								X	_	ed by More	Reporting Pe	I .	
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy											
		Ta	ble I - Non-	·Derivati	the a	affirmative o	defens	e conditions of	Rule 10b5-1(d	c). See Instru	uction 10.					
1. Title of Security (Instr. 3) 2. Trans: Date				2. Transacti	action 2A. Deemed Execution Date,		3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			ed (A) or	5. Amoun Securities Beneficia Owned Fo	s Fo ally (D) following (I)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership		
				Code V			Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		ise (Month/Day/Year) if any (Month/Day/		Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	Owner Form: Direct or Ind (I) (Ins	(D) Beneficial Ownership rect (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	Oii(8)		
Stock Option (right to buy)	\$5.77	03/13/2024		A		300,000		(1)	03/12/2034	Common Stock	300,000	\$0	300,00	00 D		

Explanation of Responses:

1. The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.

/s/ Douglas A Treco

03/15/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.